Nuwellis reported second quarter 2026 net sales of $2.0 million, a 14% increase year-over-year, with gross margin expanding to 76% from 56%. The company raised approximately $12.7 million in gross proceeds through June and July financing activities, extending its cash runway through the second quarter of 2027. Nuwellis appointed Mike McCormick as President and CEO effective June 30, 2026, and advanced an FDA label expansion for its Aquadex system to patients weighing 5 kilograms or more. The company operates in the medical technology industry, developing solutions for cardiorenal conditions.

Nuwellis, Inc. entered into a securities purchase agreement on July 31, 2026, to sell 1,310,890 shares of common stock at $2.59 per share in a registered direct offering. Concurrently, the company issued warrants to purchase an equal number of shares with an exercise price of $2.59 and a five-year term. Ladenburg Thalmann & Co. Inc. acted as placement agent for approximately $3.4 million in gross proceeds, closing on August 3, 2026. The filing also notes that Nuwellis received $3.1 million from the exercise of previously issued warrants from a June 2026 public offering. Nuwellis operates in the medical technology industry, providing solutions for patients with cardiorenal conditions.

Nuwellis, Inc. stockholders' special meeting held on July 24, 2026, approved the issuance of common stock in accordance with Nasdaq Listing Rule 5635(d) and a reverse stock split in a range of 1-for-5 to 1-for-70. The company is a medical technology company that provides solutions for fluid management.

Nuwellis, Inc. has approved a one-for-thirty-five reverse stock split of its issued and outstanding common stock. Following Board approval on June 16, 2026, the company filed a Certificate of Amendment in Delaware on June 23, 2026. The split becomes effective at 5:00 p.m. ET on June 25, 2026, with shares expected to trade on a split-adjusted basis starting June 26, 2026. Every 35 existing shares will convert into one share of common stock, and proportionate adjustments will apply to preferred stock, options, and warrants. Fractional shares will be settled in cash based on the closing price from the last trading day before the effective date. Nuwellis, Inc. is a medical device company.

Nuwellis, Inc. announced a leadership transition where John L. Erb resigned as CEO and will remain as Chairman of the Board. Michael McCormick, a medical device executive with extensive experience, was appointed as the new CEO and President and a member of the Board, effective June 30, 2026. McCormick's employment agreement includes a $431,100 annual base salary and a target 65% annual incentive compensation. The Board of Directors has also been expanded from five to six members. Nuwellis, Inc. is a medical device company focused on kidney-related technologies.